GSK

Overview

Pharmaceutical company that entered a landmark 2010 alliance with the San Raffaele/Telethon institute to co-develop gene therapies across five rare diseases, contributing GMP, regulatory filing, and commercial expertise. GSK entered a strategic alliance with the San Raffaele/Telethon institute in 2010 to co-develop gene therapies across five rare diseases, providing GMP process expertise, regulatory filing capabilities, and funding alongside the institute's scientific and clinical knowledge. The GSK partnership moved gene therapy medicines from early Phase 1 clinical trials through later phases and ultimately to market approval, demonstrating that deep academia-industry collaboration can bridge the full development pathway for rare disease gene therapies. (Segment 1 (00:00-05:00)) GSK entered a joint development collaboration with Henlius for a PD-L inhibitor targeting COPD, leveraging GSK's recognized expertise in the respiratory disease area. The GSK-Henlius deal was structured as an option program where GSK accessed Henlius's drug discovery and innovation capabilities; the deal's success directly preceded and informed the larger BMS collaboration. (Segment 2 (05:00-10:00))